MarketLens
Sign Up

What Did the Recent CARVYKTI Data Reveal About Its Potential

5 months ago
SHARE THIS ON:

What Did the Recent CARVYKTI Data Reveal About Its Potential

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

SHARE THIS ON:

Related Articles

Category

You may also like

Stock News•1 months ago

Legend Biotech Presents CARVYKTI Data Showing Half of Patients with RRMM Remained Progression-Free and Alive Five Years After a Single Infusion

Legend Biotech reported CARVYKTI data showing 50% of RRMM patients remained progression-free and alive five years after a single infusion, with a 69.2% five-year overall survival rate. The results add...
Stock News•1 months ago

Enliven Therapeutics: A Clean Active-Site TKI Could Redefine CML Sequencing

Enliven Therapeutics holds $895M cash, funding operations into 2030, after Phase 1 data showed 61% MMR at 80 mg daily for ELVN-001 in chronic myeloid leukemia, supporting earlier-line potential.
Stock News•3 months ago

Can BMY's CELMoD Program Advancements Strengthen Its Oncology Portfolio?

BMY filed for FDA approval of mezigdomide in relapsed/refractory multiple myeloma, advancing its CELMoD protein degrader pipeline.

Breaking News

View All →

Top Headlines

View More →
Stock News•26 minutes ago

Google parent Alphabet suffers nearly $500B Wall Street wipeout amid AI spending fears

Stock News•53 minutes ago

Amazon the Latest Mag 7 to Miss Q3 Estimates

Stock News•1 hour ago

20 Years of S&P 500 History Show: This Simple Strategy Is Only 8.3% Less Than "Perfect"

Stock News•1 hour ago

Microsoft Q1: Capex Shouldn't Scare You Due To Free Cash Flow

Stock News•1 hour ago

Microsoft Took The Balanced Approach To AI - Now It's The King